JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1992; 19:1123-1128
© 1992 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Topol, E.
Right arrow Articles by Califf, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Topol, E.
Right arrow Articles by Califf, R.

Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee

EJ Topol, P Armstrong, F Van de Werf, N Kleiman, K Lee, D Morris, M Simoons, G Barbash, H White, and RM Califf

Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195.

The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial is a large scale international trial of new myocardial reperfusion strategies. The primary hypothesis is that early and sustained coronary artery recanalization will be associated with a significant reduction in mortality. The four regimens that are being tested are 1) streptokinase with subcutaneous heparin; 2) streptokinase with intravenous heparin; 3) accelerated recombinant tissue-type plasminogen activator (rt-PA) with intravenous heparin; and 4) combination streptokinase, rt-PA and intravenous heparin. The planned recruitment of 41,600 patients in 1,500 sites from 15 countries is expected to be completed by December 1992 and will enable detection of a 15% reduction or 1% absolute difference in mortality compared with that associated with standard therapy (streptokinase and subcutaneous heparin). In designing the trial, two important issues were directly addressed. First, a strategy was developed to provide assurance of patient safety during large scale investigational use of an aggressive thrombolytic regimen. This includes fascimile transmission of a one-page safety summary form to the Data Coordinating Center within 24 h of death or discharge, acceptance of the concept of "net clinical benefit" and close surveillance of the trial's progress by the independent Data and Safety Monitoring Committee. Second, to avoid potential conflict of interest beyond elimination of any position of financial equity, the Steering Committee unanimously voted to prohibit any honoraria for speaking engagements, payment for consultancy or travel or reimbursement of any kind from any of the five corporate sponsors until 1 year after publication of the results. Incorporation of these approaches may facilitate the design of future large scale randomized trials in cardiovascular medicine.


This article has been cited by other articles:


Home page
JAMAHome page
J. E. Bekelman, Y. Li, and C. P. Gross
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
JAMA, January 22, 2003; 289(4): 454 - 465.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. J. Topol, M. Nurok, M. J. Ratain, M. E. Sheridan, B. Lo, L. Wolf, S. V. McCrary, L. B. McCullough, B. A. Brody, J. B. Martin, et al.
Conflict-of-Interest Policies
N. Engl. J. Med., March 29, 2001; 344(13): 1017 - 1018.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
R. Jansen, M. G. Niemeyer, T. J. Cleophas, and A. H. Zwinderman
Factors Influencing Efficacy of Nitrate Therapy for Stable Angina Pectoris: A Multiple Linear Regression Analysis
Angiology, December 1, 2000; 51(12): 1007 - 1012.
[Abstract] [PDF]


Home page
NEJMHome page
B. Lo, L. E. Wolf, and A. Berkeley
Conflict-of-Interest Policies for Investigators in Clinical Trials
N. Engl. J. Med., November 30, 2000; 343(22): 1616 - 1620.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. M. Drazen and G. Koski
To Protect Those Who Serve
N. Engl. J. Med., November 30, 2000; 343(22): 1643 - 1645.
[Full Text]


Home page
CirculationHome page
E. J. Topol, R. M. Califf, F. Van de Werf, M. Simoons, J. Hampton, K. L. Lee, H. White, J. Simes, and P. W. Armstrong
Perspectives on Large-Scale Cardiovascular Clinical Trials for the New Millennium
Circulation, February 18, 1997; 95(4): 1072 - 1082.
[Full Text]


Home page
CirculationHome page
P. W. Armstrong and C. D. Furberg
Clinical Trial Data and Safety Monitoring Boards : The Search for a Constitution
Circulation, February 1, 1995; 91(3): 901 - 904.
[Full Text]


Home page
NEJMHome page
E. J. Emanuel and D. Steiner
Institutional Conflict of Interest
N. Engl. J. Med., January 26, 1995; 332(4): 262 - 268.
[Full Text]


Home page
NEJMHome page
H. S. Friedman, L. Chelluri, C. A. Sirio, D. C. Angus, K. Ogunyankin, E. J. Topol, R. M. Califf, F. Van de Werf, and V. Fuster
Thrombolytic Therapy for Acute Myocardial Infarction: GUSTO Criticized
N. Engl. J. Med., February 17, 1994; 330(7): 504 - 506.
[Full Text]


Home page
NEJMHome page
The GUSTO Investigators
An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
N. Engl. J. Med., September 2, 1993; 329(10): 673 - 682.
[Abstract] [Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1992 by the American College of Cardiology Foundation.